Deciphera Pharmaceuticals Inc. priced a public offering of 4,300,000 common shares at $40 apiece.
The Waltham, Mass.-based biotechnology company plans to raise about $172 million in gross proceeds.
The underwriters have a 30-day option to buy up to an additional 645,000 common shares.
The offering, which is subject to customary closing conditions, is expected to close June 11.
J.P. Morgan and Piper Jaffray & Co. are joint book-running managers, while Canaccord Genuity LLC and JMP Securities LLC are acting as lead managers for the offering. Nomura Securities International Inc. and Raymond James & Associates Inc. are co-managers.
